Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송무곤 | - |
dc.date.accessioned | 2019-11-26T04:06:59Z | - |
dc.date.available | 2019-11-26T04:06:59Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.citation | ONCOTARGET, v. 8, no. 23, page. 37605-37618 | en_US |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=16790&path[]=57884 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/114505 | - |
dc.description.abstract | Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).Thirty-nine (22%) patients were aged >= 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. >= 2; p = 0.0002), beta(2)-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/m(2); p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients. | en_US |
dc.description.sponsorship | This research was supported by Janssen Korea Ltd. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | IMPACT JOURNALS LLC | en_US |
dc.subject | multiple myeloma | en_US |
dc.subject | aged | en_US |
dc.subject | bortezomib | en_US |
dc.subject | drug therapy | en_US |
dc.subject | combination | en_US |
dc.title | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | en_US |
dc.type | Article | en_US |
dc.relation.no | 23 | - |
dc.relation.volume | 8 | - |
dc.identifier.doi | 10.18632/oncotarget.16790 | - |
dc.relation.page | 37605-37618 | - |
dc.relation.journal | ONCOTARGET | - |
dc.contributor.googleauthor | Kim, Min Kyoung | - |
dc.contributor.googleauthor | Kim, Kihyun | - |
dc.contributor.googleauthor | Min, Chang-Ki | - |
dc.contributor.googleauthor | Kwak, Jae-Yong | - |
dc.contributor.googleauthor | Bae, Sang-Byung | - |
dc.contributor.googleauthor | Yoon, Sung-Soo | - |
dc.contributor.googleauthor | Lee, Je-Jung | - |
dc.contributor.googleauthor | Kim, Ki Hwan | - |
dc.contributor.googleauthor | Nam, Seung-Hyun | - |
dc.contributor.googleauthor | Song, Moo-Kon | - |
dc.relation.code | 2017009424 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | song9676 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.